secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2022-05-02T23:59:59+00:00
Accession:  0001193125-22-137040
Event type: leadership
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Cortexyme cuts 36% more staff (67% total); CMO Michael Detke departs May 2
--------------------------------------------------------------------------

- Additional 36% headcount reduction, bringing total to 67% from January 2022 levels; majority by end of May 2022.
- Estimated $0.7M in cash expenses for severance and related costs.
- CMO Michael Detke to step down effective May 2, 2022; cash severance of $354,750 (9 months base salary).
- Additional cash severance and accelerated vesting if change in control within 3 months of departure.
- Cost reductions triggered by clinical hold on atuzaginstat (COR388) IND.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312522137040/0001193125-22-137040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312522137040/d310630d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-137040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer